Wells Fargo & Company Analysts Give Mylan N.V. (MYL) a $32.00 Price Target
Mylan N.V. (NASDAQ:MYL) has been given a $32.00 price objective by equities researchers at Wells Fargo & Company in a report issued on Wednesday. The brokerage presently has a “hold” rating on the stock. Wells Fargo & Company’s price target would suggest a potential downside of 15.61% from the company’s current price.
Other research analysts have also issued research reports about the company. UBS AG reaffirmed a “buy” rating and set a $46.00 price target (down previously from $50.00) on shares of Mylan N.V. in a research report on Thursday, August 10th. Citigroup Inc. raised Mylan N.V. from a “neutral” rating to a “buy” rating and upped their price target for the company from $36.00 to $42.00 in a research report on Wednesday, August 16th. Mizuho reaffirmed a “buy” rating and set a $37.00 price target (down previously from $53.00) on shares of Mylan N.V. in a research report on Sunday, August 20th. BMO Capital Markets reaffirmed a “buy” rating and set a $45.00 price target on shares of Mylan N.V. in a research report on Friday, September 29th. Finally, ValuEngine raised Mylan N.V. from a “hold” rating to a “buy” rating in a research report on Monday. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Mylan N.V. currently has an average rating of “Buy” and a consensus price target of $42.04.
Shares of Mylan N.V. (NASDAQ:MYL) traded up 0.32% during midday trading on Wednesday, reaching $37.92. The company’s stock had a trading volume of 11,211,385 shares. The company’s 50-day moving average price is $31.86 and its 200 day moving average price is $36.48. The company has a market capitalization of $20.34 billion, a P/E ratio of 30.65 and a beta of 1.30. Mylan N.V. has a 12-month low of $29.39 and a 12-month high of $45.87. Mylan N.V. also saw some unusual options trading on Wednesday. Stock investors acquired 10,562 put options on the stock. This represents an increase of 461% compared to the typical volume of 1,883 put options.
Mylan N.V. (NASDAQ:MYL) last released its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 EPS for the quarter, missing analysts’ consensus estimates of $1.18 by ($0.08). The business had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $3 billion. Mylan N.V. had a net margin of 5.51% and a return on equity of 22.42%. The company’s revenue for the quarter was up 15.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.16 EPS. On average, equities research analysts forecast that Mylan N.V. will post $4.52 earnings per share for the current year.
A number of hedge funds have recently bought and sold shares of MYL. Waldron LP bought a new position in Mylan N.V. during the 1st quarter valued at approximately $229,000. UBS Asset Management Americas Inc. increased its position in Mylan N.V. by 13.7% during the 1st quarter. UBS Asset Management Americas Inc. now owns 1,179,217 shares of the company’s stock valued at $45,978,000 after buying an additional 142,124 shares in the last quarter. Sei Investments Co. increased its position in Mylan N.V. by 1.0% during the 1st quarter. Sei Investments Co. now owns 13,870 shares of the company’s stock valued at $541,000 after buying an additional 134 shares in the last quarter. KBC Group NV increased its position in Mylan N.V. by 27.5% during the 1st quarter. KBC Group NV now owns 49,272 shares of the company’s stock valued at $1,921,000 after buying an additional 10,638 shares in the last quarter. Finally, Blair William & Co. IL increased its position in Mylan N.V. by 20.3% during the 1st quarter. Blair William & Co. IL now owns 9,591 shares of the company’s stock valued at $401,000 after buying an additional 1,616 shares in the last quarter. 71.97% of the stock is owned by institutional investors.
About Mylan N.V.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.